AnaptysBio, Inc.
ANAB
$20.24
-$0.12-0.59%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -38.63M | -39.33M | -21.78M | -32.85M | -46.66M |
| Total Depreciation and Amortization | 601.00K | 606.00K | 601.00K | 596.00K | 595.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.25M | 25.56M | 23.29M | 21.04M | 16.02M |
| Change in Net Operating Assets | -29.46M | 2.46M | -68.78M | 1.13M | 8.72M |
| Cash from Operations | -40.24M | -10.70M | -66.67M | -10.09M | -21.32M |
| Capital Expenditure | -39.00K | -35.00K | -263.00K | -35.00K | -33.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 36.44M | 14.88M | -29.13M | 58.66M | -2.41M |
| Cash from Investing | 36.40M | 14.85M | -29.40M | 58.62M | -2.44M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.42M | 290.00K | 555.00K | 98.50M | 979.00K |
| Repurchase of Common Stock | -51.10M | -4.42M | -456.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -823.00K | -24.46M | 27.47M | -27.27M | 40.91M |
| Cash from Financing | -50.50M | -28.59M | 27.57M | 71.23M | 41.89M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -54.34M | -24.44M | -68.50M | 119.76M | 18.13M |